*B-YOND is the extension study to B-LONG and Kids B-LONG.5
EHL, extended half-life; FIX, factor IX; PTP, previously treated patient; PUP, previously untreated patient.
References
1. ALPROLIX Package Insert FDA. Revised May 2023. 2. Powell JS, et al. N Engl J Med. 2013;369(24):2313–2323. 3. Fischer K, et al. Lancet Haematol. 2017;4(2):e75–e82. 4. Nolan B, et al. Blood Adv. 2021;5(13):2732–2739. 5. Pasi KJ, et al. Haemophilia. 2020;26(6):e262–e271. 6. Shapiro A, et al. Blood Adv. 2023;7(13):3049–3057. 7. Rebinyn Package Insert. FDA. Revised August 2022. 8. Idelvion Package Insert. FDA. Revised June 2023. 9. ALPROLIX UK Summary of Product Characteristics. 10. ALPROLIX EU Summary of Product Characteristics.
ALPROLIX is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). ALPROLIX can be used for all age groups.9,10
Adverse events should be reported. Reporting forms and information can be found, for United Kingdom: via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For Ireland: via HPRA Pharmacovigilance website www.hpra.ie. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd by email at [email protected] or by calling +44 (0) 800 111 4754. |